CAR T cells bi-specific for CD13 and TIM3, which is upregulated in AML leukemia stem cells, eradicated patient-derived AML, with much reduced toxicity to human bone marrow stem cells and peripheral myeloid cells in mouse models, highlighting a promising approach for developing effective AML CAR...
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 ...
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial Article Open access 07 August 2024 Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, with nearly 60,000 expected new di...
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality. LEARN MORE NOVEL TECHNOLOGY NEW SOLUTION Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell cu...
BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target immunotherapy. Bispecific CARs are proposed to mitigate these limitations. Methods We constructed...
Explore BPS Bioscience’s services for bispecific antibodies and BiTEs. Discover our solutions for developing and optimizing bispecific T-cell engager therapies.
My impression is they’re a lot less toxic than CAR [chimeric antigen receptor] T cells, and I suspect they could probably be delivered safely as an outpatient from the majority of patients, particularly if you had some home monitoring system you could use. Also, to go back to CAR T, ...
Immunotherapies – such as checkpoint inhibitors and chimeric antigen receptor T-cells (CAR-Ts) – have transformed cancer treatment in the past decade, but the vast majority of patients still do not experience meaningful or durable benefits from these breakthrough therapies. While some may see tha...
“CD3 bispecifics would be considered direct competitors to CAR-T,” asserts Desjarlais. CAR T-cell therapies require weeks of preparation including cellular extraction from a patient, engineering in vitro, culturing, speculative dosing, and continued growth in vivo. In contrast, Desjarlais points...